ALN-HSD
NASH (Non-alcoholic Steatohepatitis)
Phase 1Active
Key Facts
Indication
NASH (Non-alcoholic Steatohepatitis)
Phase
Phase 1
Status
Active
Company
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.
View full company profileTherapeutic Areas
Other NASH (Non-alcoholic Steatohepatitis) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Internal Program | Viscient Biosciences | Preclinical |
| Undisclosed In-licensed Program | Viscient Biosciences | Phase 2 |
| EDL6D | EndoLipiD Therapeutics | Preclinical |